Head of Research, Krungthai XSpring

Waraporn Wiboonkanarak

Head of Research

A full service Thai brokerage

Krungthai XSpring

Krungthai XSpring is a full service broker. The company provides a wide range of investment services such as Securities Brokerage, Derivative Agent Business, Securities Borrowing and Lending, Securities Trading, Underwriting, Financial Advisory, Wealth Advisory, Private Fund Management and International Markets Securities Trading. 

In terms of credibility, Fitch Ratings has assigned Krunghtai XSpring a long-term rating of AA- and a national short-term rating of F1+ with stable outlook.

Thematic (Sector/Industry)

<ul><li>Vaccine stocks (NVAX, BNTX, PFE, MRNA, PCVX) had a good week, as the FDA provided new regulatory policy for COVID-19 vaccines.</li><li>While more restrictive and unconventionally delivered in a NEJM op-ed, the publication reduced uncertainty for vaccine makers and gave full support for the measles vaccine by FDA heads.</li><li>Biopharma shrugged off MFN pricing targets, as implementation remained unclear. </li></ul>

Vaccine stocks (NVAX, BNTX, PFE, MRNA, PCVX) had a good week, as the FDA provided new regulatory policy for COVID-19 vaccines.While more restrictive and unconventionally delivered in a NEJM op-ed, the publication reduced uncertainty for vaccine makers and gave full support for the measles vaccine by FDA heads.Biopharma shrugged off MFN pricing targets, as implementation remained unclear. 

Biopharma Week in Review - FDA Provides Some Certainty for Vaccines; ASCO Abstracts Snippets

New Zealand Professional Investment Services Firm, Forsyth Barr

Forsyth Barr

New Zealand Professional Investment Services Firm

We are proud to be a New Zealand owned firm, with 21 offices throughout the country and over 300 employees. We assist personal, institutional and corporate clients providing a full range of investment services.

Forsyth Barr is a foundation New Zealand Exchange firm (NZX) and accredited market participant. We have been confirmed by the Financial Markets Authority as a Qualifying Financial Entity (QFE).

Research is the cornerstone of our advice. We have one of New Zealand's leading teams of analysts. Our global affiliations ensure comprehensive research coverage of all major investment markets.

Equity Bottom-Up

<ul><li>AFT Pharmaceuticals (AFT) hosted a forward-looking investor day highlighting its attractive R&amp;D pipeline.</li><li>In the meantime, AFT’s operating business continues to perform strongly, with management reiterating FY27 guidance for revenue of &gt;NZ$300m, up &gt;+18% year-on-year, and EBIT of NZ$28m–NZ$32m (FB estimate: ~NZ$31m).</li><li>We retain OUTPERFORM, with the risk–reward still skewed to the upside.</li></ul>

AFT Pharmaceuticals (AFT) hosted a forward-looking investor day highlighting its attractive R&amp;D pipeline.In the meantime, AFT’s operating business continues to perform strongly, with management reiterating FY27 guidance for revenue of &gt;NZ$300m, up &gt;+18% year-on-year, and EBIT of NZ$28m–NZ$32m (FB estimate: ~NZ$31m).We retain OUTPERFORM, with the risk–reward still skewed to the upside.

AFT Pharmaceuticals Pipeline Prescribes Upside

<ul><li>The SET Index is expected to move sideways up, with the resistance at 1,650/1,666 points and the support at 1,631 points (10-day EMA)/1,620 points (25-day EMA).</li><li>We recommend trading buy on COM7, SPVI and BDMS.</li><li>Technically, the index seems to have remained in an uptrend, with continued increases in the low and high points each day; there will be more buy signs if it surpasses the previous resistance at 1,650 points.</li></ul>

The SET Index is expected to move sideways up, with the resistance at 1,650/1,666 points and the support at 1,631 points (10-day EMA)/1,620 points (25-day EMA).We recommend trading buy on COM7, SPVI and BDMS.Technically, the index seems to have remained in an uptrend, with continued increases in the low and high points each day; there will be more buy signs if it surpasses the previous resistance at 1,650 points.

United States

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Merck & (MRK UN)

Biopharma Week in Review - FDA Provides Some Certainty for Vaccines; ASCO Abstracts Snippets

Vaccine stocks (NVAX, BNTX, PFE, MRNA, PCVX) had a good week, as the FDA provided new regulatory policy for COVID-19 vaccines.

Krungthai XSpring

AFT Pharmaceuticals Pipeline Prescribes Upside

AFT Pharmaceuticals (AFT) hosted a forward-looking investor day highlighting its attractive R&D pipeline. In the meantime, AFT’s operating...

Forsyth Barr

Market Outlook and Recommendations

The SET Index is expected to move sideways up, with the resistance at 1,650/1,666 points and the support at 1,631 points (10-day EMA)/1,620 points...

Krungthai XSpring

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)